A Study to Evaluate the Safety and Efficacy of RQC for AMD
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Paul A Knepper, MD, PhD
Zaparackas Knepper, Ltd
Principal Investigator - Zibute Zaparackas, MD
Zaparackas Knepper, Ltd
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Zaparackas M.D. & Knepper M.D. Ph.D., Ltd
Chicago, Illinois, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Oct 2021
- Primary completion
- 7 Nov 2024
- Completion
- 7 Nov 2024
- Last update posted
- 30 Jul 2025
- Registered enrollment
- 55
- Registry id
- NCT05062486
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.